Tetralogic Pharmaceuticals (TLOG) began trading on the NASDAQ on 12 December 2013

• The stock reached $9.71 in 2013 and $5.19 in 2014 during its active clinical development phase.
• TetraLogic restructured its convertible senior notes and voluntarily delisted its common stock from NASDAQ, moving to the OTC market under the ticker TLOG.PK.

TetraLogic Pharmaceuticals Corporation (TetraLogic) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing novel small molecule therapeutics that mimic Second Mitochondrial Activator of Caspases (SMAC)-mimetics, and are designed to cause or enable abnormal cells that are resistant to the body's immune system to self-destruct. Birinapant, its clinical-stage product candidate, is being tested in Phase I and Phase II oncology clinical trials for multiple solid tumors and hematological malignancies. The Company’s clinical trials of birinapant have enrolled over 275 subjects. The Company’s lead program is colorectal cancer (CRC), where it has substantially completed a Phase I/II clinical trial. TetraLogic's lead Smac mimetic drug, birinapant (formerly TL32711), is in Phase II clinical trials and is being developed for both solid tumors and hematological malignancies as a single agent and in combination with several standard-of-care cancer therapies.

Address

343 PHOENIXVILLE PIKE
MALVERN, PA 19355
United States

Website 

www.tetralogicpharma.com